Director/PDMR Shareholding

AstraZeneca PLC
28 February 2007


Dealing by Directors
Companies Act 1985 Sections 324/329


Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R


We hereby inform you that the interest of David R. Brennan, a Director of the
Company, in the shares of AstraZeneca PLC has changed as detailed below.  Mr
Brennan has interests in both the Ordinary Shares and the American Depositary
Shares (ADSs) of AstraZeneca PLC.  One ADS equals one Ordinary Share.

On 23 February 2007, Mr Brennan received an allocation of 12,014 Ordinary Shares
under the previously disclosed arrangements relating to his annual bonus for
2006 whereby he is required to defer a portion of the bonus earned into shares
for a period of three years.  The shares were allocated at a price of 2911 pence
per share.  Mr Brennan will become beneficially entitled to these shares on 23
February 2010.

On 23 February 2007, Mr Brennan received a scheduled distribution out of the
AstraZeneca US Executive Deferral Plan, a unitised stock fund established in
2000, in which Mr Brennan, in common with other participating US executives, is
deemed to have a notional interest in ADSs calculated by reference to the fund
value and the closing price of AstraZeneca ADSs.  Following this scheduled
distribution on 23 February 2007, Mr Brennan had a notional interest in 54,313
ADSs within the AstraZeneca US Executive Deferral Plan by reference to the
closing price on 23 February 2006 of US$57.19.

On 26 February 2007, Mr Brennan purchased, on his own account, additional ADSs
to be held within the AstraZeneca US Executive Deferral Plan bringing his
notional interest in ADSs held within the AstraZeneca US Executive Deferral Plan
as at 26 February 2007 to 62,192 ADSs based on that day's closing price of
US$57.30.

On 28 February 2007, Mr Brennan purchased, on his own account, 5,000 additional
ADSs at a price of $56.34 per ADS to be held in a personal brokerage account.

Immediately prior to the above transactions, Mr Brennan had an interest in
98,553 Ordinary Shares and 170,538 AstraZeneca ADSs.  As a result of these
transactions, Mr Brennan's interest is now 110,567 Ordinary Shares and 160,297
AstraZeneca ADSs, including the notional interest in ADSs in the AstraZeneca US
Executive Deferral Plan referred to above.  This interest represents
approximately 0.018% of the Company's issued ordinary capital.


G H R Musker
Company Secretary
28 February 2007



                      This information is provided by RNS
            The company news service from the London Stock Exchange